ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint? and BluePri
b3cnewswire
December 04, 2017Agendia, Inc., a global leader in personalized medicine and molecular cancer diagnostics, announces the value of its upcoming MammaPrint?70-Breast Cancer Recurrence Risk Test and BluePrint? Breast Cancer Molecular Subtype Test at the upcoming 2017 San Ant
Pharma Sources Insight January 2025
